These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 12954580

  • 1. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.
    Tambaro R, Greggi S, Iaffaioli RV, Rossi A, Pisano C, Manzione L, Ferrari E, Di Maio M, Iodice F, Casella G, Laurelli G, Pignata S.
    Ann Oncol; 2003 Sep; 14(9):1406-11. PubMed ID: 12954580
    [Abstract] [Full Text] [Related]

  • 2. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
    Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A, Varvara F, Colombo A, Ferrera P.
    Oncology; 2002 Sep; 63(1):23-30. PubMed ID: 12187067
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of Doxil and vinorelbine in patients with advanced malignancies.
    Laufman LR, Spiridonidis CH, Jones JJ, Rhodes V, Rossi K, Wallace K.
    Cancer Invest; 2004 Sep; 22(3):344-52. PubMed ID: 15493354
    [Abstract] [Full Text] [Related]

  • 4. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE, Fine S, Gelmon K, Rudinskas L, Ottaway J, Myles J, James K, Paul K, Rodgers A, Pritchard KI.
    Cancer Chemother Pharmacol; 1997 Sep; 41(1):53-60. PubMed ID: 9443614
    [Abstract] [Full Text] [Related]

  • 5. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E, Amarantidis K, Trichas M, Vasiliadis M, Toromanidou M, Chatzaki E, Karayiannakis A, Tsaroucha A, Romanidis K, Kakolyris S.
    Oncology; 2005 Sep; 69(6):463-9. PubMed ID: 16374040
    [Abstract] [Full Text] [Related]

  • 6. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT.
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
    Bakker M, Groen HJ, Smit EF, Smeets J, Riggi M, Postmus PE.
    Br J Cancer; 1995 Dec; 72(6):1547-50. PubMed ID: 8519675
    [Abstract] [Full Text] [Related]

  • 11. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
    Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U.
    Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP.
    Cancer Chemother Pharmacol; 1999 Jan; 43(1):68-72. PubMed ID: 9923543
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
    Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F, MITO Investigators.
    BMC Cancer; 2006 Aug 01; 6():202. PubMed ID: 16882344
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
    Fracasso PM, Blum KA, Tan BR, Fears CL, Bartlett NL, Arquette MA, Clark RS.
    Cancer; 2002 Nov 15; 95(10):2223-9. PubMed ID: 12412177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.